Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma Article Swipe
Thomas M. Anderson
,
Bryan H. Chang
,
Alexander C. Huang
,
Xiaowei Xu
,
Daniel Yoon
,
Catherine G. Shang
,
Rosemarie Mick
,
Erin Schubert
,
Suzanne McGettigan
,
Kristin Kreider
,
Wei Xu
,
E. John Wherry
,
Lynn M. Schuchter
,
Ravi K. Amaravadi
,
Tara C. Mitchell
,
Michael D. Farwell
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.25728812
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.25728812
Supplementary Figure S2. Change in SUVmax versus percentage of Ki67+ CD8 T cells.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.25728812
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4396543811
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4396543811Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.25728812Digital Object Identifier
- Title
-
Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced MelanomaWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-05-01Full publication date if available
- Authors
-
Thomas M. Anderson, Bryan H. Chang, Alexander C. Huang, Xiaowei Xu, Daniel Yoon, Catherine G. Shang, Rosemarie Mick, Erin Schubert, Suzanne McGettigan, Kristin Kreider, Wei Xu, E. John Wherry, Lynn M. Schuchter, Ravi K. Amaravadi, Tara C. Mitchell, Michael D. FarwellList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.25728812Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.25728812Direct OA link when available
- Concepts
-
Pembrolizumab, Medicine, Nuclear medicine, Melanoma, Positron emission tomography, Medical physics, Radiology, Internal medicine, Cancer, Immunotherapy, Cancer researchTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4396543811 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.25728812 |
| ids.doi | https://doi.org/10.1158/1078-0432.25728812 |
| ids.openalex | https://openalex.org/W4396543811 |
| fwci | 0.0 |
| type | preprint |
| title | Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9986000061035156 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T12422 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9793000221252441 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2741 |
| topics[1].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[1].display_name | Radiomics and Machine Learning in Medical Imaging |
| topics[2].id | https://openalex.org/T11533 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9790999889373779 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Melanoma and MAPK Pathways |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780057760 |
| concepts[0].level | 4 |
| concepts[0].score | 0.891414225101471 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[0].display_name | Pembrolizumab |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7030487060546875 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2989005 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5861756205558777 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[2].display_name | Nuclear medicine |
| concepts[3].id | https://openalex.org/C2777658100 |
| concepts[3].level | 2 |
| concepts[3].score | 0.547863781452179 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q180614 |
| concepts[3].display_name | Melanoma |
| concepts[4].id | https://openalex.org/C2775842073 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4559285640716553 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q208376 |
| concepts[4].display_name | Positron emission tomography |
| concepts[5].id | https://openalex.org/C19527891 |
| concepts[5].level | 1 |
| concepts[5].score | 0.42515838146209717 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1120908 |
| concepts[5].display_name | Medical physics |
| concepts[6].id | https://openalex.org/C126838900 |
| concepts[6].level | 1 |
| concepts[6].score | 0.36645224690437317 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q77604 |
| concepts[6].display_name | Radiology |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.30815547704696655 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.1136903166770935 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C2777701055 |
| concepts[9].level | 3 |
| concepts[9].score | 0.09050863981246948 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[9].display_name | Immunotherapy |
| concepts[10].id | https://openalex.org/C502942594 |
| concepts[10].level | 1 |
| concepts[10].score | 0.08090931177139282 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[10].display_name | Cancer research |
| keywords[0].id | https://openalex.org/keywords/pembrolizumab |
| keywords[0].score | 0.891414225101471 |
| keywords[0].display_name | Pembrolizumab |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7030487060546875 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/nuclear-medicine |
| keywords[2].score | 0.5861756205558777 |
| keywords[2].display_name | Nuclear medicine |
| keywords[3].id | https://openalex.org/keywords/melanoma |
| keywords[3].score | 0.547863781452179 |
| keywords[3].display_name | Melanoma |
| keywords[4].id | https://openalex.org/keywords/positron-emission-tomography |
| keywords[4].score | 0.4559285640716553 |
| keywords[4].display_name | Positron emission tomography |
| keywords[5].id | https://openalex.org/keywords/medical-physics |
| keywords[5].score | 0.42515838146209717 |
| keywords[5].display_name | Medical physics |
| keywords[6].id | https://openalex.org/keywords/radiology |
| keywords[6].score | 0.36645224690437317 |
| keywords[6].display_name | Radiology |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.30815547704696655 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.1136903166770935 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/immunotherapy |
| keywords[9].score | 0.09050863981246948 |
| keywords[9].display_name | Immunotherapy |
| keywords[10].id | https://openalex.org/keywords/cancer-research |
| keywords[10].score | 0.08090931177139282 |
| keywords[10].display_name | Cancer research |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.25728812 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.25728812 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5072684110 |
| authorships[0].author.orcid | https://orcid.org/0009-0005-6695-3239 |
| authorships[0].author.display_name | Thomas M. Anderson |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Thomas M. Anderson |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5003008865 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-1875-5001 |
| authorships[1].author.display_name | Bryan H. Chang |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Bryan H. Chang |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5081974951 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-0099-0492 |
| authorships[2].author.display_name | Alexander C. Huang |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Alexander C. Huang |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5101814553 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-4098-7690 |
| authorships[3].author.display_name | Xiaowei Xu |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Xiaowei Xu |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5063042794 |
| authorships[4].author.orcid | https://orcid.org/0009-0006-0172-5558 |
| authorships[4].author.display_name | Daniel Yoon |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Daniel Yoon |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5048546352 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-7541-5513 |
| authorships[5].author.display_name | Catherine G. Shang |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Catherine G. Shang |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5052264374 |
| authorships[6].author.orcid | https://orcid.org/0009-0004-6215-0538 |
| authorships[6].author.display_name | Rosemarie Mick |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Rosemarie Mick |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5066610065 |
| authorships[7].author.orcid | https://orcid.org/0009-0001-9105-5829 |
| authorships[7].author.display_name | Erin Schubert |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Erin Schubert |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5011640449 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-7922-8360 |
| authorships[8].author.display_name | Suzanne McGettigan |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Suzanne McGettigan |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5088126621 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Kristin Kreider |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Kristin Kreider |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5102027063 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Wei Xu |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Wei Xu |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5057824723 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-0477-1956 |
| authorships[11].author.display_name | E. John Wherry |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | E. John Wherry |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5012671311 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Lynn M. Schuchter |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Lynn M. Schuchter |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5009482043 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-5768-2474 |
| authorships[13].author.display_name | Ravi K. Amaravadi |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Ravi K. Amaravadi |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5012202516 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-8186-7284 |
| authorships[14].author.display_name | Tara C. Mitchell |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Tara C. Mitchell |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5066628879 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-0650-4747 |
| authorships[15].author.display_name | Michael D. Farwell |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Michael D. Farwell |
| authorships[15].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.25728812 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9986000061035156 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W2585407512, https://openalex.org/W3037068108, https://openalex.org/W2059423835, https://openalex.org/W2945780494, https://openalex.org/W3041652591, https://openalex.org/W2517747645, https://openalex.org/W2062691140, https://openalex.org/W2067378624, https://openalex.org/W4299869620, https://openalex.org/W2420408560 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.25728812 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.25728812 |
| primary_location.id | doi:10.1158/1078-0432.25728812 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.25728812 |
| publication_date | 2024-05-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.T | 11 |
| abstract_inverted_index.in | 4 |
| abstract_inverted_index.of | 8 |
| abstract_inverted_index.CD8 | 10 |
| abstract_inverted_index.S2. | 2 |
| abstract_inverted_index.Ki67+ | 9 |
| abstract_inverted_index.Change | 3 |
| abstract_inverted_index.Figure | 1 |
| abstract_inverted_index.SUVmax | 5 |
| abstract_inverted_index.versus | 6 |
| abstract_inverted_index.percentage | 7 |
| abstract_inverted_index.cells.</p> | 12 |
| abstract_inverted_index.<p>Supplementary | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 16 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6299999952316284 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.12078632 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |